A Monoclonal Antibody for Malaria Prevention

New England Journal of Medicine
August 26, 2021 Vol. 385 No. 9


Original Articles
A Monoclonal Antibody for Malaria Prevention M.R. Gaudinski and Others
Among adults who had never had malaria infection or vaccination, administration of the long-acting monoclonal antibody CIS43LS prevented malaria after controlled infection. (Funded by the National Institute of Allergy and Infectious Diseases; VRC 612 ClinicalTrials.gov number, NCT04206332. opens in new tab.)